Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 7/20 | 0.36 |
| ▸ | LOX | P28300 | 1/20 | 0.35 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.35 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6213044 | 0.86 | MMP13 (0.38) | MMP13CETP | |
| SCHEMBL6842418 | 0.86 | FFAR1 (0.39) | FFAR1MMP13 | |
| SCHEMBL6209461 | 0.84 | VKORC1 (0.43) | FFAR1CETP | |
| SCHEMBL6213824 | 0.84 | MMP13 (0.40) | FFAR1MMP13 | |
| SCHEMBL6209706 | 0.84 | MMP13 (0.40) | FFAR1MMP13 | |
| SCHEMBL6212049 | 0.83 | MMP13 (0.42) | FFAR1MMP13 | |
| SCHEMBL6194203 | 0.83 | MMP13 (0.42) | MMP13CETPPDE3BPDE3APDE10A | |
| SCHEMBL6194194 | 0.83 | MMP13 (0.42) | MMP13CETPPDE3BPDE3APDE10A | |
| SCHEMBL6843278 | 0.82 | CYP11B1 (0.42) | FFAR1LOXLOXL2ACACBPLA2G7 | |
| SCHEMBL6844622 | 0.81 | KDM4E (0.40) | FFAR1MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | LI JIE JACK (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043983-A1 | Naphthalene derivatives as matrix metalloproteinase inhibitors | MMP9, MMP8, MMP13 | FFAR1 2162/4885MMP13 3/4885LOX 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.